A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Background: EP0057 (formerly CRLX101) is an investigational nanoparticle-drug conjugate (NDC) of a cycloclextrin-based polymer backbone plus camptothecin, a topoisomerase-1 inhibitor. Prior studies showed efficacy in recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC). Methods: This phase Ib/2 trial assessed safety and efficacy of EP0057 Q2W plus weekly paclitaxel in patients with EOC. The recommended phase 2 dose (RP2D) was identified using a 3+3 design. The single-arm phase 2 assessed overall response (ORR) per RECIST 1.1 in patients previously treated with bevacizumab. Secondary objectives included progression free survival (PFS) and duration of response. Results: The RP2D was established as 15 mg/m(2) EP0057 Q2W plus 80 mg/m(2) paclitaxel administered 3 weeks on/i week off. Nine patients enrolled on phase 1b, with no DLTs; 21 additional patients enrolled on phase 2. All completed >= 1 cycle. Median age was 62 (44-76) years, 57%>= 3 prior therapies. For the primary analysis, 6/19 patients with prior bevacizumab had confirmed responses (ORR= 31.6% (95% CI: 15.4% to 54.0%)) including one complete response (CR). Median PFS was 5.4 months. Most common grade 3/4 adverse events attributed to treatment were decreased neutrophil count (13, 43%) and anemia (3, 10%). Conclusions: Although the observed ORR was not statistically better than the historical control rate, EP0057 remains an interesting option for treatment of recurrent EOC. EP0057 exhibits high plasma drug retention, slow clearance, and controlled slow release of CPT from the polymer when administered alone and with paclitaxel. (C) 2020 Elsevier Inc. All rights reserved.

Automated summary

EP0057, an investigational nanoparticle-drug conjugate, in combination with paclitaxel has shown efficacy in treating recurrent EOC, with a recommended phase 2 dose of 15 mg/m(2) EP0057 every 2 weeks plus 80 mg/m(2) paclitaxel weekly. Although the observed overall response rate was not statistically better than historical control rate, EP0057 remains an interesting option for treatment of recurrent EOC.